Navigation Links
New Post Hoc Analyses Examined the Effects of Neupro® (Rotigotine Transdermal System) on Daytime Functioning, Daytime Symptoms, Pain and Mood in Restless Legs Syndrome
Date:6/10/2011

pro® has been associated with somnolence episodes of sudden sleep onset episodes. Patients treated with dopamine agonists including Neupro®, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality.

Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore it is recommended to taper treatment.

Neupro® contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.

Hallucinations have been reported, and patients should be informed that hallucinations can occur.

Cases of cardiopulmonary fibrotic complications have been reported in some patients treated with ergot-derived dopaminergic agents. Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists. Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.

External heat, from any source should not be applied to the area of the patch. Exposure of a skin rash or irritation to direct sunlight could lead to changes in the skin color. If a generalized skin reaction (e.g. allergic rash) associated with the use of Neupro® is observed, Neupro® should be discontinued.

Caution is advised when treating patients with severe hepatic impairment or acute worsening of renal function, a dose reduction might be needed.

The incidence of some dopaminergic adverse events, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa. This should be considered when prescribing Neupro®.

Neupro® should not be used during pregnancy. Breast-feeding should be discontinued.

Augmentation may occur in Restless Legs Syndrome patients. Augmentation refers to the earlier onset of
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015   Mallinckrodt ... biopharmaceutical company, will present at the Barclays Global Healthcare ... Miami, Florida , on Wednesday, March 11, 2015. Mark ... represent the company in a session scheduled to begin ... attend the meeting in person can find webcast information ...
(Date:3/4/2015)...   Symbiomix Therapeutics , a late-stage, privately ... women,s health infections, today announced results from its ... product candidate, SYM-1219, was safe and well tolerated ... efficacy for birth control pills would not be ... will be presented on March 6 th ...
(Date:3/3/2015)... -- Actavis plc (NYSE: ACT ) today ... billion aggregate principal amount of senior unsecured notes in ... issued by its indirect wholly-owned subsidiary, Actavis Funding SCS, ... "Notes"), as follows: Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... $500,000,000 , Due 2016 , 100.00% 1.850% ...
Breaking Medicine Technology:Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... and live webcast on Wednesday, November 2, 2011 at 9:00 ... The Company will release its financial results on November 2, ... live webcast can be made via the Company,s website at ...
... 2011 The Infectious Disease Research Institute (IDRI) announces ... broad range of instrumentation and equipment that will assist ... the burden of disease in the developing world. IDRI ... trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, ...
Cached Medicine Technology:GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:3/4/2015)... (PRWEB) March 04, 2015 The popular ... of their new L-Style Revolution™ Program. The customized program ... and women of all health and fitness levels to ... goals faster than traditional methods. , “We’re really proud ... customized plans based on award winning techniques to help ...
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is ... joined the company as Chief Technology Officer. Mr. Dvorak ... the company, including customer-centric strategies and initiatives, and promoting ... experience as a technology executive and visionary. Prior to ... FBI including oversight of enterprise data management, analytic software ...
(Date:3/4/2015)... New Port Richey, FL (PRWEB) March 04, 2015 ... Novus Medical Detox cut the ribbon on their new facility ... West Pasco Chamber of Commerce. The new facility will allow ... mission of helping end the prescription drug abuse epidemic through ... the current reality of drug addiction in the United States, ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... have been selected by Chase Brexton Health Care, ... announced today. , Chase Brexton provides comprehensive primary ... than 30,000 patients across seven clinics in the ... adopters of electronic medical records, the organization has ...
(Date:3/4/2015)... Dietary supplement company MitoSynergy will showcase ... chelate, at Natural Products Expo West 2015 at booth ... insight into their wellness through a free ZYTO scan ... their individual nutritional needs, all while relaxing in a ... of the MitoSynergy product line, was developed to provide ...
Breaking Medicine News(10 mins):Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2
... Charity Event to benefit Breast Cancer ResearchFORT LAUDERDALE, Fla., ... are invited to join Ladies Sail for a Cure, ... to raise money for the Florida Breast Cancer Coalition ... charity sailing event organized by eBoatCharters.com. The sailing catamaran, ...
... Your animal buddy can,t read it. Your vet may not read it. But you ... That,s the reason Jim Schwartz wrote the book:, , ... to stop harmful over-vaccination of our pets; , ... your animal companion; , to describe an insurance ...
... BEACH, Calif., Jan. 22 Forterus Healthcare, a division ... that it has acquired Solutions 4 Recovery, a Dana ... expected to close Feb. 1 2009Forterus Healthcare will operate ... Forterus, Inc. Solutions 4 Recovery is the second behavioral ...
... to be Presented at This Week,s Keystone Symposium - ... WALTHAM, Mass., Jan. 22 Interleukin Genetics, Inc. (NYSE ... present new research findings on the role genetics play ... fat while following a calorie-restricted diet, during tomorrow,s Keystone ...
... Hospital for Children has achieved Magnet designation for excellence ... (ANCC) Magnet Recognition Program(R). Magnet recognition is one ... medical center can achieve. "The Magnet recognition is ... but it doesn,t change who we are," says Karen ...
... - at the Pravasi Bharatiya Divas convention in Chennai, January 7-10, ... the world,s first comprehensive health care organization with an emphasis on ... ... Chennai (PRWEB) January 22, 2009 -- At the Pravasi ...
Cached Medicine News:Health News:Ladies Set Sail to Raise Money for a Cure 2Health News:Why Your Pet Wants You to Read 'Trust Me: I'm Not a Veterinarian!': Jim Schwartz's New Book Is a Self-Defense Manual for Animal Guardians 2Health News:Forterus Healthcare to Acquire Solutions 4 Recovery 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 3Health News:St. Christopher's Hospital for Children Earns National Recognition for Nursing Excellence 2Health News:Doctors of Indian origin unite to tackle global health problems - the creation of The first ever Global Association of Physicians of Indian Origin (GAPIO) 2Health News:Doctors of Indian origin unite to tackle global health problems - the creation of The first ever Global Association of Physicians of Indian Origin (GAPIO) 3
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: